Marshall Wace North America L.P. boosted its holdings in Exponent, Inc. (NASDAQ:EXPO) by 58.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 33,627 shares of the business services provider’s stock after buying an additional 12,431 shares during the period. Marshall Wace North America L.P. owned approximately 0.06% of Exponent worth $1,941,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in EXPO. Thrivent Financial for Lutherans raised its holdings in Exponent by 0.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 36,680 shares of the business services provider’s stock worth $1,860,000 after purchasing an additional 247 shares during the period. Oregon Public Employees Retirement Fund increased its position in shares of Exponent by 1.8% during the first quarter. Oregon Public Employees Retirement Fund now owns 20,144 shares of the business services provider’s stock worth $1,163,000 after acquiring an additional 364 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Exponent by 0.3% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 123,509 shares of the business services provider’s stock worth $6,263,000 after acquiring an additional 366 shares in the last quarter. Bank of Montreal Can increased its position in shares of Exponent by 5.3% during the fourth quarter. Bank of Montreal Can now owns 7,404 shares of the business services provider’s stock worth $376,000 after acquiring an additional 370 shares in the last quarter. Finally, Mason Street Advisors LLC increased its position in shares of Exponent by 2.4% during the first quarter. Mason Street Advisors LLC now owns 16,539 shares of the business services provider’s stock worth $955,000 after acquiring an additional 387 shares in the last quarter. Institutional investors and hedge funds own 88.80% of the company’s stock.
A number of research analysts have recently commented on EXPO shares. Cantor Fitzgerald reissued a “buy” rating on shares of Tivity Health in a research report on Monday, April 22nd. Zacks Investment Research raised shares of Focus Financial Partners from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research report on Monday, June 24th. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, William Blair restated a “market perform” rating on shares of W W Grainger in a research note on Monday, April 22nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. Exponent presently has an average rating of “Hold” and a consensus price target of $61.33.
Exponent (NASDAQ:EXPO) last released its earnings results on Thursday, April 18th. The business services provider reported $0.42 EPS for the quarter, beating the consensus estimate of $0.35 by $0.07. Exponent had a net margin of 19.53% and a return on equity of 23.10%. The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.52 million. During the same period last year, the firm earned $0.75 EPS. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. As a group, equities research analysts forecast that Exponent, Inc. will post 1.42 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, June 21st. Shareholders of record on Friday, June 7th were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 1.06%. The ex-dividend date of this dividend was Thursday, June 6th. Exponent’s dividend payout ratio is currently 51.20%.
In related news, Director Carol Lindstrom sold 1,800 shares of Exponent stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $56.92, for a total transaction of $102,456.00. Following the sale, the director now directly owns 3,212 shares of the company’s stock, valued at approximately $182,827.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.30% of the stock is owned by company insiders.
Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company worldwide. Its services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property, and impending litigation.
Further Reading: Why does the United States have a lingering trade deficit?
Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.